Methionine Aminopeptidase 2 - Pipeline Review, H2 2019
Methionine Aminopeptidase 2 - Pipeline Review, H2 2019
SUMMARY
According to the recently published report 'Methionine Aminopeptidase 2 - Pipeline Review, H2 2019'; Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) pipeline Target constitutes close to 11 molecules.
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Methionine aminopeptidase 2 is an enzyme that in humans is encoded by the METAP2 gene. Methionine aminopeptidase 2 is a member of the dimetallohydrolase family is a cytosolic metalloenzyme that catalyzes the hydrolytic removal of N-terminal methionine residues from nascent proteins. Increased expression of this METAP2 is associated with various forms of cancer, and the anti-cancer drugs fumagillin and ovalicin inhibit the protein by irreversibly binding to its active site. Inhibitors of METAP2 have shown to be effective for the treatment of obesity.
The report 'Methionine Aminopeptidase 2 - Pipeline Review, H2 2019' outlays comprehensive information on the Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 3, 3 and 2 respectively. Report covers products from therapy areas Metabolic Disorders, Oncology, Gastrointestinal, Genetic Disorders and Infectious Disease which include indications Obesity, Non-Alcoholic Steatohepatitis (NASH), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Prostate Cancer, Solid Tumor, Giardiasis, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Prostate Cancer, Prader-Willi Syndrome (PWS) and Type 2 Diabetes.
SCOPE
SUMMARY
According to the recently published report 'Methionine Aminopeptidase 2 - Pipeline Review, H2 2019'; Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) pipeline Target constitutes close to 11 molecules.
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Methionine aminopeptidase 2 is an enzyme that in humans is encoded by the METAP2 gene. Methionine aminopeptidase 2 is a member of the dimetallohydrolase family is a cytosolic metalloenzyme that catalyzes the hydrolytic removal of N-terminal methionine residues from nascent proteins. Increased expression of this METAP2 is associated with various forms of cancer, and the anti-cancer drugs fumagillin and ovalicin inhibit the protein by irreversibly binding to its active site. Inhibitors of METAP2 have shown to be effective for the treatment of obesity.
The report 'Methionine Aminopeptidase 2 - Pipeline Review, H2 2019' outlays comprehensive information on the Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 3, 3 and 2 respectively. Report covers products from therapy areas Metabolic Disorders, Oncology, Gastrointestinal, Genetic Disorders and Infectious Disease which include indications Obesity, Non-Alcoholic Steatohepatitis (NASH), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Prostate Cancer, Solid Tumor, Giardiasis, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Prostate Cancer, Prader-Willi Syndrome (PWS) and Type 2 Diabetes.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18)
- The report reviews Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics and enlists all their major and minor projects
- The report assesses Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Overview
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Companies Involved in Therapeutics Development
Asieris Pharmaceuticals Co Ltd
Chong Kun Dang Pharmaceutical Corp
Merck KGaA
Primetime Life Sciences LLC
SynDevRx Inc
Takeda Pharmaceutical Co Ltd
Zafgen Inc
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Drug Profiles
APL-1301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
beloranib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fumagillin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-8891 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitroxoline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLS-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SDX-7195 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SDX-7320 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MAP2 for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZGN-1061 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZGN-1345 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Dormant Products
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Discontinued Products
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Product Development Milestones
Featured News & Press Releases
Jul 24, 2019: Zafgen announces agreement With U.S. Food And Drug Administration on new nonclinical study design for ZGN-1061
Jun 26, 2019: Asieris concludes enrolment for Phase Ib trial of APL-1202
Jun 10, 2019: Zafgen presented full results of Phase 2 clinical trial for ZGN-1061 at the American Diabetes Association's 79th Scientific Sessions
May 30, 2019: Zafgen announces regulatory update on ZGN-1061
Jan 17, 2019: Zafgen announces positive results for second cohort of phase 2 clinical trial of ZGN-1061
Nov 26, 2018: Zafgen provides update on investigational new drug application for ZGN-1061
Nov 01, 2018: Asieris announced appointment of Dr. Gail Brown as acting Chief Medical Officer
Jun 25, 2018: Zafgen to Host ZGN-1061 Phase 2 Data Conference Call
Jun 23, 2018: Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes
May 30, 2018: Asieris Awarded Best Poster at AUA 2018 Annual Meeting
Mar 06, 2018: Zafgen Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes
Jan 05, 2018: Zafgen Provides Update on its Obesity Drug candidate ZGN-1061
Sep 12, 2017: Zafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes
Sep 12, 2017: Zafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of the European Association for the Study of Diabetes
Aug 24, 2017: Asieris Pharmaceuticals Invited to Present at the 20th Annual Meeting of CSCO
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Overview
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Companies Involved in Therapeutics Development
Asieris Pharmaceuticals Co Ltd
Chong Kun Dang Pharmaceutical Corp
Merck KGaA
Primetime Life Sciences LLC
SynDevRx Inc
Takeda Pharmaceutical Co Ltd
Zafgen Inc
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Drug Profiles
APL-1301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
beloranib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fumagillin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-8891 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitroxoline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLS-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SDX-7195 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SDX-7320 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MAP2 for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZGN-1061 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZGN-1345 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Dormant Products
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Discontinued Products
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Product Development Milestones
Featured News & Press Releases
Jul 24, 2019: Zafgen announces agreement With U.S. Food And Drug Administration on new nonclinical study design for ZGN-1061
Jun 26, 2019: Asieris concludes enrolment for Phase Ib trial of APL-1202
Jun 10, 2019: Zafgen presented full results of Phase 2 clinical trial for ZGN-1061 at the American Diabetes Association's 79th Scientific Sessions
May 30, 2019: Zafgen announces regulatory update on ZGN-1061
Jan 17, 2019: Zafgen announces positive results for second cohort of phase 2 clinical trial of ZGN-1061
Nov 26, 2018: Zafgen provides update on investigational new drug application for ZGN-1061
Nov 01, 2018: Asieris announced appointment of Dr. Gail Brown as acting Chief Medical Officer
Jun 25, 2018: Zafgen to Host ZGN-1061 Phase 2 Data Conference Call
Jun 23, 2018: Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes
May 30, 2018: Asieris Awarded Best Poster at AUA 2018 Annual Meeting
Mar 06, 2018: Zafgen Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes
Jan 05, 2018: Zafgen Provides Update on its Obesity Drug candidate ZGN-1061
Sep 12, 2017: Zafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes
Sep 12, 2017: Zafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of the European Association for the Study of Diabetes
Aug 24, 2017: Asieris Pharmaceuticals Invited to Present at the 20th Annual Meeting of CSCO
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Asieris Pharmaceuticals Co Ltd, H2 2019
Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019
Pipeline by Merck KGaA, H2 2019
Pipeline by Primetime Life Sciences LLC, H2 2019
Pipeline by SynDevRx Inc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Zafgen Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Asieris Pharmaceuticals Co Ltd, H2 2019
Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019
Pipeline by Merck KGaA, H2 2019
Pipeline by Primetime Life Sciences LLC, H2 2019
Pipeline by SynDevRx Inc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Zafgen Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Asieris Pharmaceuticals Co Ltd
Chong Kun Dang Pharmaceutical Corp
Merck KGaA
Primetime Life Sciences LLC
SynDevRx Inc
Takeda Pharmaceutical Co Ltd
Zafgen Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Asieris Pharmaceuticals Co Ltd
Chong Kun Dang Pharmaceutical Corp
Merck KGaA
Primetime Life Sciences LLC
SynDevRx Inc
Takeda Pharmaceutical Co Ltd
Zafgen Inc
